What was Immage Biotherapeutics’s price range in the past 12 months?
Immage Biotherapeutics lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is Immage Biotherapeutics’s market cap?
Immage Biotherapeutics’s market cap is $152.
When is Immage Biotherapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
Is Immage Biotherapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Immage Biotherapeutics pay dividends?
Immage Biotherapeutics does not currently pay dividends.
What is Immage Biotherapeutics’s EPS estimate?
Immage Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immage Biotherapeutics have?
Immage Biotherapeutics has 151,744,570 shares outstanding.
Which hedge fund is a major shareholder of Immage Biotherapeutics?
Currently, no hedge funds are holding shares in IMMG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immage Biotherapeutics
Presently, Immage Biotherapeutics Corp. lacks substantial business operations. Historically, its endeavors centered on the creation of cutting-edge immunotherapy biologics designed to combat diverse cancer types across the United States. Established in 2012, the entity was initially known as Epicure Charcoal, Inc., rebranding to Immage Biotherapeutics Corp. in June 2015. Its corporate headquarters are situated in Bethesda, Maryland, and it operates as a subsidiary of Coventry International Limited.